Bcr-abl tyrosine kinase inhibitor

DRUG CLASS:

Bcr-abl tyrosine kinase inhibitor

News alerts, weekly reports and conference planners

Related drugs:

KIT positive	Gastrointestinal Stromal Tumor	KIT positive	Gastrointestinal Stromal Tumor	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	asciminib Sensitive: A1 - Approval asciminib Sensitive : A1	asciminib Sensitive: A1 - Approval asciminib Sensitive : A1
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	asciminib Sensitive: A1 - Approval asciminib Sensitive : A1	asciminib Sensitive: A1 - Approval asciminib Sensitive : A1
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	nilotinib Sensitive: A1 - Approval nilotinib Sensitive : A1	nilotinib Sensitive: A1 - Approval nilotinib Sensitive : A1
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	bosutinib Sensitive: A1 - Approval bosutinib Sensitive : A1	bosutinib Sensitive: A1 - Approval bosutinib Sensitive : A1
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1
No biomarker	Fibrosarcoma	No biomarker	Fibrosarcoma	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
KIT expression	Gastrointestinal Stromal Tumor	KIT expression	Gastrointestinal Stromal Tumor	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
FIP1L1-PDGFRA fusion	Chronic Eosinophilic Leukemia	FIP1L1-PDGFRA fusion	Chronic Eosinophilic Leukemia	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
PDGFRA rearrangement	Myelodysplastic Syndrome	PDGFRA rearrangement	Myelodysplastic Syndrome	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
PDGFRA mutation	Gastrointestinal Stromal Tumor	PDGFRA mutation	Gastrointestinal Stromal Tumor	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2
BCR-ABL1 V299L	Acute Lymphocytic Leukemia	BCR-ABL1 V299L	Acute Lymphocytic Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 F317I	Acute Lymphocytic Leukemia	BCR-ABL1 F317I	Acute Lymphocytic Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 T315I	Acute Lymphocytic Leukemia	BCR-ABL1 T315I	Acute Lymphocytic Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2
BCR-ABL1 V299L	Chronic Myeloid Leukemia	BCR-ABL1 V299L	Chronic Myeloid Leukemia	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2
BCR-ABL1 T315I	Acute Lymphocytic Leukemia	BCR-ABL1 T315I	Acute Lymphocytic Leukemia	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2
BCR-ABL1 T315I	Acute Lymphocytic Leukemia	BCR-ABL1 T315I	Acute Lymphocytic Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	bosutinib Sensitive: A2 - Guideline bosutinib Sensitive : A2	bosutinib Sensitive: A2 - Guideline bosutinib Sensitive : A2
No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2
No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
ABL2 fusion	Childhood B Acute Lymphoblastic Leukemia	ABL2 fusion	Childhood B Acute Lymphoblastic Leukemia	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
No biomarker	Chordoma	No biomarker	Chordoma	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	bosutinib Sensitive: A2 - Guideline bosutinib Sensitive : A2	bosutinib Sensitive: A2 - Guideline bosutinib Sensitive : A2
BCR-ABL1 E255V	Acute Lymphocytic Leukemia	BCR-ABL1 E255V	Acute Lymphocytic Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2

Bcr-abl tyrosine kinase inhibitor

Bcr-abl tyrosine kinase inhibitor

Associations(521)

Associations
(521)